Phoenix Bio



HepDART 2015でのPXBマウスおよびPXB-cells関連研究発表のご案内


2015年 12月6日(日)~12月10日(木)にGrand Wailea(Maui, Hawaii)にて開催されましたHepDART 2015


Oral Presentation

Session Title: The Tide has shifted Toward HBV Cure and Treatment for NASH

“Cyclophilin Inhibitors and Their Potential as Therapeutics for the Treatment of HBV”

Dr. Michael Sofia, Arbutus Biopharma Corporation, USA


“Preclinical and Clinical Profile of NVR 3-778, a First-In-Class HBV Core Inhibitor for the Treatment of Chronic Hepatitis B”

Dr. Osvaldo Flores, Novira Therapeutics, USA


“RG-101, a Novel microRNA Therapeutic to Target the Host Factor of HCV”

Dr. Paul Grint, Regulus Therapeutics, USA

Poster Presentation

Session Title: Next Generation of Anti-Hepatitis Inhibitors

Abstract #110

“4′-Modified Nucleoside Analogs: Potent Inhibitors Active against Entecavir Resistant Hepatitis B Virus (HBV) and their Structure-Activity Relationship”

Dr. Hiroaki Mitsuya, Kumamoto University, Japan


Abstract #111

“BB-HB-331, a DNA-Directed RNA Interference Agent (ddRNAi) for the Treatment of Subjects Infected with the Hepatitis B Virus (HBV), Can Effectively Suppress HBV in a Primary Hepatocyte Model”

Dr. David Suhy, Benitec Biopharma, USA